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Abstract
Background: Collagen deposition and an altered matrix metalloproteinase (MMP) expression profile are hallmarks
of fibrosis. Type IV collagen is the most abundant structural basement membrane component of tissue, which
increases 14-fold during fibrogenesis in the liver. Proteolytic degradation of collagens by proteases produces small
fragments, so-called neoepitopes, which are released systemically. Technologies investigating MMP-generated
fragments of collagens may provide more useful information than traditional serological assays that crudely
measure total protein. In the present study, we developed an ELISA for the quantification of a neoepitope
generated by MMP degradation of type IV collagen and evaluated the association of this neoepitope with liver
fibrosis in two animal models.
Methods: Type IV collagen was degraded in vitro by a variety of proteases. Mass spectrometric analysis revealed
more than 200 different degradation fragments. A specific peptide sequence, 1438’GTPSVDHGFL’1447 (CO4-MMP),
in the a1 chain of type IV collagen generated by MMP-9 was selected for ELISA development. ELISA was used to
determine serum levels of the CO4-MMP neoepitope in two rat models of liver fibrosis: inhalation of carbon
tetrachloride (CCl4) and bile duct ligation (BDL). The levels were correlated to histological findings using Sirius red
staining.
Results: A technically robust assay was produced that is specific to the type IV degradation fragment,
GTPSVDHGFL. CO4-MMP serum levels increased significantly in all BDL groups compared to baseline, with a
maximum increase of 248% seen two weeks after BDL. There were no changes in CO4-MMP levels in sham-
operated rats. In the CCl4 model, levels of CO4-MMP were significantly elevated at weeks 12, 16 and 20 compared
to baseline levels, with a maximum increase of 88% after 20 weeks. CO4-MMP levels correlated to Sirius red
staining results.
Conclusion: This ELISA is the first assay developed for assessment of proteolytic degraded type IV collagen, which,
by enabling quantification of basement membrane degradation, could be relevant in investigating various
fibrogenic pathologies. The CO4-MMP degradation fragment was highly associated with liver fibrosis in the two
animal models studied.
Keywords: biochemical marker, type IV collagen, neoepitope, basement membrane, extracellular matrix, liver fibro-
sis, protease-cleaved fragment, matrix metalloproteinase 9
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Background
Liver fibrosis due to viral or alcohol-induced injury is
one of the leading causes of death worldwide [1]. To
date, no curative treatment for liver fibrosis is available,
and patients are dependent on the success of inactiva-
tion or removal of the injurious agent or, in the case of
end-stage cirrhosis, on liver transplantation. Assessment
of liver fibrosis is important to estimate the prognosis
for patients with liver cirrhosis and to determine surveil-
lance strategies. At present, liver biopsy is the most
common method used to assess fibrosis, but it is inva-
sive and associated with patient discomfort and, in rare
cases, serious complications [2]. In addition, the accu-
racy of liver biopsy is limited because of sampling error
and significant intra- and interobserver variability in his-
tological staging [3,4]. Therefore, research has focused
on the evaluation of noninvasive methods for the assess-
ment of liver fibrosis [5].
The process leading to liver fibrosis resembles the
process of wound healing, including the three phases
following tissue injury: inflammation, synthesis of col-
lagenous and noncollagenous extracellular matrix
(ECM) components, and tissue remodeling.
Basement membranes in tissues are thin, sheetlike
extracellular structures that provide tissue structure and
influence cell behavior. The basement membrane is
composed of several proteins, such as type IV collagen,
laminin, proteoglycans and entactin/nidogen [6]. The
presence and distribution of these proteins vary between
different tissues. During the pathogenesis of liver fibro-
sis, the basement membrane components collagen type
IV, entactin and laminin increase and form a basement
membrane-like structure within the space of Disse [6].
Type IV collagen is the most abundant structural
basement membrane component. It consists of a major
triple-helix flanked by an N-terminal 7S domain and a
C-terminal noncollagenous domain, NC1. There are six
distinct type IV collagen chains, a1-a6(IV), that display
tissue-specific distribution patterns. Three a chains fold
to form a heterotrimeric molecule called a protomer [7].
Remarkably, the six genetically distinct a chains assem-
ble to form only three protomers: a1a1a2(IV), a3a4a5
(IV) and a5a5a6(IV). The major ubiquitous form of
type IV collagen, a1a1a2(IV), is present in the base-
ment membranes of all tissues, whereas the other two
protomers display a more restricted pattern of distribu-
tion. Once the protomer is secreted, a complex set of
interactions takes place between protomers, forming a
collagen type IV network in the shape of a lattice. The
important structural role of collagen type IV is illu-
strated by the clinical consequences of collagen IV
mutations, such as Alport syndrome [8,9].
Endopeptidases such as matrix metalloproteinases
(MMPs) play a major part in the degradation of
extracellular macromolecules such as collagens, and dur-
ing fibrogenesis, the levels of MMPs increase [10,11].
With respect to excessive proteolytic activity in the
fibrous tissue, the gelatinase MMP-9 has been investi-
gated and documented to be highly regulated [10,11].
As a consequence of tissue turnover caused by fibro-
sis, there is a systemic release of several protein degra-
dation fragments specific for the combination of the
involved proteases (such as MMP, the affected organ
and the disease). The fragmentation results in the expo-
sure of new peptide ends (so-called neoepitopes), to
which specific antibodies can be developed. These neoe-
pitopes may be useful molecular biochemical markers
[12].
We hypothesized that it is possible during liver fibro-
genesis to measure serum type IV collagen that has
been degraded by a specific MMP (MMP-9). The aim of
this work was to develop a novel, competitive ELISA for
measuring MMP-9-mediated turnover of type IV col-
lagen and to measure the neoepitope 1438’GTPSV
DHGFL’1447 (CO4-MMP) in two complementary
experimental models of liver fibrosis induced by bile
duct ligation (BDL) or carbon tetrachloride (CCl4).
Materials and methods
Reagents
All reagents used for the experiments were standard
high-quality chemicals obtained from companies such as
Merck (Whitehouse Station, NJ, USA) and Sigma-
Aldrich (St Louis, MO, USA). The synthetic peptides
used for monoclonal antibody production were pur-
chased from the Chinese Peptide Company, Beijing,
China.
In vitro cleavage
Purified type IV collagen from human placenta (cat. no.
11-511-248457; GenWay Biotech, Inc., San Diego, CA,
USA) was cleaved with pro-MMP-2 (cat. no. 444213;
Calbiochem, Gibbstown, NJ, USA) or pro-MMP-9 (cat.
no. 444231; Merck, Whitehouse Station, NJ, USA). Fifty
micrograms of MMP-2 or MMP-9 were activated with
20 μL of 1 mM 4-aminophenylmercuric acetate in
dimethyl sulfoxide and incubated at 37°C for three
hours. Type IV collagen was delivered dissolved in 0.5
M acetic acid. To facilitate MMP cleavage, the protein
was dialyzed for two days to remove the acetic acid.
The liquid was filtered to remove proteins below 10
kDa (cat. no. 42407, Microcon Ultracel YM-10; Milli-
pore, Billerica, MA, USA). Each MMP cleavage was per-
formed separately by mixing 100 μg of type IV collagen
and 10 μg of either MMP-2 or MMP-9 in MMP buffer
(100 mM Tris·HCl, 100 mM NaCl, 10 mM CaCl2, 2
mM Zn acetate, pH 8.0). As a control, 100 μg of col-
lagen was mixed with MMP buffer alone. The solutions
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were incubated for two hours at 37°C. The cleavage
reaction was stopped using 50 μM ethylenediaminete-
traacetic acid (EDTA) to a final concentration of 1 μM.
Cleavage was verified by visualization using the SilverX-
press Silver Staining Kit (cat. no. LC6100; Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions.
Peptide identification
Peptide fragments in the in vitro cleaved samples were
identified using liquid chromatography (LC) coupled to
electrospray ionization (ESI) tandem mass spectrome-
try (LC-MS/MS). LC-MS samples were ultrafiltrated to
remove proteins above 10 kDa, the pH was adjusted to
2.0 using formic acid and a 4 μL sample was analyzed
by LC-MS/MS. LC was performed on a nanoAC-
QUITY UPLC BEH C18 Column (Waters, Milford,
MA, USA) using a formic acid/acetonitrile gradient.
MS and MS/MS were performed on a Synapt G1 High
Definition Mass Spectrometer quadrupole time-of-
flight MS (QUAD-TOF; Waters) with an acquisition
range of 350 to 1,600 m/z in MS and 50 to 2000 m/z
in MS/MS. ProteinLynx Global SERVER software
(Waters) was used to analyze spectra and generate
peak lists. To identify peptides, MS and MS/MS data
were searched against a type IV collagen protein data-
base (FASTA) using Mascot 2.2 software (Matrix
Science, Boston, MA, USA) with the ESI-QUAD-TOF
settings and carbamidomethyl (C), oxidation of
methionine (M), oxidation of lysine (K) and oxidation
of proline (P) as variable modifications.
The six amino acids in the N- or C-terminal of the
peptides identified by MS were regarded as a neoepitope
generated by the protease in question. All protease-gen-
erated sequences were analyzed for homology and dis-
tance to other cleavage sites and tested for homology
using NPS@:network protein sequence analysis [13].
Peptide conjugation
The peptide conjugation was performed using the Mal-
eimide Activated BSA, KLH Conjugation Kit (Sigma-
Aldrich). Briefly, the cysteine-containing immunogenic
neoepitope (CGG-GTPSVDHGFL, 400 μL of peptide at
5 mg/mL) with one free sulfhydryl group (-SH) was
mixed in conjugation buffer containing the maleimide-
activated ovalbumin (OVA) (180 μL of OVA at 10 mg/
mL) as a carrier protein with an available maleimide
group that could react with -SH-containing peptides
and incubated for two hours at room temperature.
Conjugated products were cleared of EDTA and
sodium azide by desalting or dialysis for two days. The
biotin-conjugated lysine was added to the biotin-conju-
gated peptides in the solid-phase peptide synthesis
procedure.
Monoclonal antibody development
Four- to six-week-old Balb/c mice were immunized sub-
cutaneously with about 200 μL of emulsified antigen
and 50 μg of the neoepitope CO4-MMP (OVA-CGG-
GTPSVDHGFL). Consecutive immunizations were per-
formed at two-week intervals until stable sera titer levels
were reached in Freund’s incomplete adjuvant. Blood
samples were collected from the second immunization.
For each blood sampling, the serum titer was deter-
mined and the mouse with the highest antiserum titer
was selected for fusion. After the fourth immunization,
this mouse was rested for one month and then boosted
intravenously with 50 μg of CO4-MMP in 100 μL of
0.9% sodium chloride solution three days before isola-
tion of the spleen for cell fusion.
Fusion and antibody screening
The fusion procedure was performed as described by
Gefter et al. [14]. Briefly, mouse spleen cells were fused
with SP2/0 myeloma fusion partner cells. The hybri-
doma cells were cloned using a semisolid medium
method, transferred into 96-well microtiter plates for
further growth and incubated in a CO2 incubator. Stan-
dard limited dilution was used to promote monoclonal
growth. Supernatants were screened using an indirect
ELISA with streptavidin-coated microtiter plates and
biotin-CGG-GTPSVDHGFL as a capture peptide.
Characterization of clones
Native reactivity and peptide binding of the monoclonal
antibodies were evaluated by displacement of native
samples (human/rat/mouse serum, plasma and urine) in
a preliminary ELISA using 10 ng/mL biotinylated pep-
tide coater on a streptavidin-coated microtiter plate and
the supernatant from the growing monoclonal hybri-
doma. Specificities of the clones to a free peptide
(GTPSVDHGFL), a non-sense peptide and an elongated
peptide (TPSVDHGFLV) were tested. Isotyping of the
monoclonal antibodies was performed using the Clono-
typing System-HRP kit (cat. no. 5300-05; Southern Bio-
tech, Birmingham, AL, USA). The selected clones were
purified using protein G columns according to the man-
ufacturer’s instructions (GE Healthcare Life Sciences,
Little Chalfont, UK). Selected monoclonal antibodies
were labeled with horseradish peroxidase (HRP) using
the Lightning-Link Horseradish Peroxidase labeling kit
(Innova Biosciences, Cambridge, UK) according to the
instructions of the manufacturer.
CO4-matrix metalloproteinase enzyme-linked
immunosorbent assay methodology
In preliminary experiments, we optimized the reagents,
their concentrations and the incubation periods by per-
forming several checkerboard analyses. The CO4-MMP
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ELISA was developed as follows: A 96-well streptavidin
plate was coated with biotinylated synthetic peptide bio-
tin-CGG-GTPSVDHGFL, dissolved in PBS buffer (2
mM KH2PO4, 9 mM Na2HPO4, 2H2O, 3 mM KCl, 137
mM NaCl, pH 7.4) and incubated for 30 minutes at 20°
C by constant shaking at 200 rpm. Twenty microliters
of peptide calibrator or sample dissolved in assay buffer
(25 mM Tris, 1% BSA, 0.1% Tween 20, pH 7.4) were
added to appropriate wells, followed by 100 μL of conju-
gated monoclonal antibody, and incubated for one hour
at 20°C by constant shaking at 300 rpm. Finally, 100 μL
of tetramethylbenzidine (TMB) (cat. no. 438OH; Kem-
En-Tec, Copenhagen, Denmark) were added, and the
plate was incubated for 15 minutes at 20°C in the dark
and shaken at 300 rpm. After each incubation step, the
plate was washed five times in washing buffer (20 mM
Tris, 50 mM NaCl, pH 7.2). The TMB reaction was
stopped by adding 100 μL of stopping solution (1%
HCl) and measured spectrophotometrically at 450 nm
with 650 nm as the reference. A standard curve was
performed by serial dilution of the CO4-MMP peptide
and plotted using a four-parametric mathematical fit
model. Standard concentrations were 0, 1.5625, 3.125,
6.25, 12.5, 25, 50 and 100 ng/mL.
Technical evaluation
From twofold dilutions of pooled serum and plasma
samples, linearity was calculated as a percentage of
recovery of the 100% sample. The lower detection limit
(LDL) was calculated from 21 determinations of the
lowest standard (the zero standard) and calculated as
the mean 3 × standard deviation. The inter- and intraas-
say variations were determined by ten independent runs
of five QC samples, with each run consisting of two
replicates of double-determinations of the samples. Spik-
ing recovery was determined by comparing different
concentrations of a peptide sample in buffer and in
human serum. The peptide sample was the type IV col-
lagen cleaved with MMP-9 and pepsin. Finally, for each
assay, a master calibrator prepared from synthetic pep-
tides accurately quantified by amino acid analysis was
used for calibration purposes. The analyte stability was
determined for six serum samples (three rat and three
human) for ten freeze-thaw cycles.
Enzyme-linked immunosorbent assay characterization
The developed CO4-MMP ELISA was evaluated using
20 μL of the samples: intact type IV collagen, type IV
collagen cleaved with pepsin, type IV collagen cleaved
with MMP-2, type IV collagen cleaved with MMP-9,
type IV collagen cleaved with MMP-9 and pepsin, and
an elongated CO4-MMP amino acid sequence
(TPSVDGHFLV). Cross-reactivity was tested using in
vitro cleaved collagen type I or type VI.
Bile duct ligation
A total of 81 female Sprague-Dawley rats, age six
months, were housed at the animal research facilities
at Nordic Bioscience A/S, Herlev, Denmark. The
experiments were approved by the Experimental Ani-
mal Committee of the Danish Ministry of Justice and
were performed according to the European Standard
for Good Clinical Practice (2008/561-1450). The rats
were housed in standard cages at 18°C to 22°C with
bedding and nest material (1324 TPF; Altromin Spe-
zialfutter GmbH & Co. KG, Lage, Germany) and tap
water ad libitum. The rats were kept under 12-hour
light-dark cycle conditions. Experiments began after
one week of acclimatization. Liver fibrosis was
induced in anesthetized rats by standard BDL in
which the bile duct was ligated in two places and dis-
sected between the ligations prior to closing the abdo-
men. In sham-operated rats, the abdomen was closed
without BDL.
The rats were divided into four groups: rats in group 1
(ten BDL and eight sham) were killed after one week,
rats in group 2 (12 BDL and 8 sham) were killed after
two weeks, rats in group 3 (13 BDL and 8 sham) were
killed after three weeks and rats in group 4 (14 BDL
and 8 sham) were killed after four weeks.
Carbon tetrachloride inhalation
The study included 52 three-month-old male Wistar
rats treated with CCl4 and 28 Wistar control rats
(Charles River Laboratories, Saint-Aubin-lès-Elbeuf,
France). Complete details of the study are described
elsewhere [15]. Liver damage was induced as previously
described [16] and, in short, included inhalation of CCl4
twice weekly. Phenobarbital (0.3 g/L) was added to the
drinking water. Animals were stratified into groups
receiving 8, 12, 16 or 20 weeks of CCl4 (for each group,
n = 13 CCl4 and n = 7 control). Control rats received
phenobarbital only. After the stated weeks of CCl4
administration, the rats were weighed, anesthetized with
pentobarbital (50 mg/kg) and killed by decapitation. The
study was performed according to the criteria of the
Investigation and Ethics Committee of the Hospital
Clinic Universitari (Barcelona, Spain).
Blood and tissue sampling
Blood samples were taken under light CO2/O2 anesthe-
sia at baseline and at death from the retroorbital sinuses
of rats that had been fasted for at least 14 hours. The
collected blood was left for 30 minutes at room tem-
perature to clot, followed by centrifugation at 3,000 g
for 10 minutes. All clot-free liquid was transferred to
new tubes and centrifuged again at 3,000 g for 10 min-
utes. The serum was then transferred to clean tubes and
stored at -80°C.
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The livers were carefully dissected, weighed, fixed in
4% formaldehyde for a minimum of 24 hours, cut into
appropriate slices and embedded in paraffin. Liver sec-
tions (4 to 5 μm thick) were stained with 0.1% Sirius
red F3B (Sigma-Aldrich) in saturated picric acid (Sigma-
Aldrich).
Histological image analysis
Relative fibrosis area (expressed as a percentage of
total liver area) was assessed by analyzing 36 fields of
Sirius red-stained liver sections per animal. Each field
was acquired at ×10 magnification using an E600
microscope (Nikon Instruments Inc., Melville, NY,
USA) equipped with a SPOT RT Slider CCD digital
camera (Diagnostic Instruments, Inc., Sterling
Heights, MI, USA). The results were analyzed using a
computerized Bioquant Life Science morphometric
software system (Bioquant Image Analysis Corp.,
Nashville, TN, USA. To evaluate the relative fibrosis
area, the measured collagen area was divided by the
net field area and then multiplied by 100. Subtraction
of vascular luminal area from the total field area
yielded the final calculation of the net fibrosis area.
For each animal analyzed, the amount of fibrosis was
measured as a percentage and the average value is
presented [17].
Immunohistochemistry
Liver sections (4 to 5 μm) were deparaffinized and
hydrated, and further peroxidase activity was blocked
with the addition of 0.4% hydrogen peroxide. Sections
were then incubated with a polyclonal antibody against
type IV collagen (1:100; Abcam, Cambridge, UK). Sec-
tions were then rinsed, and the antibody binding was
depicted using the Super Sensitive Polymer-HRP IHC
Detection System combined with AEC substrate accord-
ing to the supplier’s instructions (Biogenex, Taby, Swe-
den). Sections were counterstained with Mayer’s
hematoxylin. Digital photographs were taken using an
Olympus B 60 × microscope at ×40 magnification
equipped with an Olympus C-5050 Zoom digital camera
(Olympus, Tokyo, Japan).
Statistical analysis
Mean values and standard errors of the mean (SEM)
were calculated using GraphPad Prism software (Graph-
Pad Software, San Diego, CA, USA), and statistical sig-
nificance was assessed using the Student’s two-tailed
paired t-test (a = 0.05) assuming normal distribution or
the Mann-Whitney two-tailed nonparametric U test (a
= 0.05). The coefficient of correlation (R2) and the cor-
responding P values were determined by linear
regression.
Results
In vitro cleavage and selection of peptides
Fragments of type IV collagen cleaved by MMP-2 or
MMP-9 with a statistically significant Mascot score (P <
0.05) were identified. All protease-generated neoepitopes
were tested for homology. Among more than 200 MMP-
generated neoepitopes, five sequences were selected for
immunization, as these sequences are unique to type IV
collagen. In addition, the sequences 3 to 5 were found in
various animal species. The five sequences selected were
(1) 328’PGPPGIVIGT.’337, CO4a1 generated by MMP-9;
(2) 333’.IVIGTGPLGE’342, CO4a1 generated by MMP-9;
(3) 777’.LQGIRGEPGP’786, CO4a1 generated by MMP-
9; (4) 1330’DQGDQGVPGA’1339, CO4a1 generated by
MMP-2 or MMP-9; and 1438’GTPSVDHGFL’1447,
CO4a1 generated by MMP-2 or MMP-9.
The sequence 1438’GTPSVDHGFL’1447 (CO4-MMP)
in the a1 chain of type IV collagen generated by MMP-
2 or MMP-9 was selected as having the best technical
performance because the antibodies were able to distin-
guish between cleaved and uncleaved type IV collagen.
This sequence was 100% homologous in human, rat and
mouse.
Clone characterization
After the fusion between spleen cells and myeloma cells,
seven hybridoma cell lines remained. After comparing
native reactivity, antibody affinity and stability, the best
antibody-producing cell line was chosen. The clone
selected was the immunoglobulin G2a subtype. The
antibody was reactive to human, rat and mouse plasma
and serum (Figure 1).
Technical evaluation
The typical standard curve is presented in Figure 2,
which shows a four-parametric fit for the assay. The
LDL for the CO4-MMP assay was 0.61 ng/ml. Dilution
recovery was within 100% ± 20% (Table 1) for human
and rat serum. The mean intra- and interassay varia-
tions were 4.8% and 12.1%, respectively (Table 2). Ana-
lyte stability was acceptable for 2 × to 10 × freeze-thaw
cycles for both rat and human serum (Table 3). The
percentages are within 100 ± 20%, except for one deter-
mination at 8 × for human serum and one determina-
tion at 6 × for rat serum. Finally, spiking recovery of
peptide in human serum was acceptable, with recoveries
ranging from 103% to 110% (Table 4).
Enzyme-linked immunosorbent assay characterization
To characterize the analytes detected in the assay, differ-
ent collagens were cleaved with different proteases. Pep-
sin or MMP-9 alone or together was able to generate
the CO4-MMP fragment from collagen type IV alone
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(Figure 2). In contrast, the fragment was not found in
intact type IV collagen or MMP-2 cleaved type IV col-
lagen. Finally, no cross-reactivity was seen between
CO4-MMP and MMP-9 cleaved type I or VI collagens,
which have high homology with the immunization
sequence of type IV collagen. No reactivity was seen
against the elongated synthetic peptide, proving neoepi-
tope reactivity (Figure 2).
Evaluations performed in the bile duct ligation study
During the four-week experiment, 15 of 81 rats, 14 of
them BDL-operated, were killed because of excessive
weight loss. CO4-MMP serum levels increased signifi-
cantly in all BDL groups compared with baseline (group
1: baseline 35.1 ng/mL, death 64.1 ng/mL, P < 0.05;
group 2: baseline 34.2 ng/mL, death 84.9 ng/mL, P <
0.01; group 3: baseline 42.9 ng/mL, death 87.4 ng/mL, P
< 0.01; group 4: baseline 40.1 ng/mL, death 88.7 ng/mL,
P < 0.001), with the maximum increase from baseline of
248% seen in group 2. CO4-MMP levels did not change
significantly in the sham-operated rats (Figure 3).
Evaluations performed in the carbon tetrachloride study
Four rats in the CCl4 groups died during the study.
Among the surviving animals, levels of CO4-MMP were
significantly elevated at all time points compared to
baseline levels, except at week 8 (week 12: control 24.6
ng/mL, CCl4 33.5 ng/mL, P < 0.05; week 16: control
24.5 ng/mL, CCl4 36.9 ng/mL, P < 0.01; week 20: con-
trol 23.0 ng/mL, CCl4 43.3 ng/mL, P < 0.01) (Figure 4).
The immunohistochemistry showed that collagen type
IV deposition was exclusively in the venous wall and
around the space of Disse in control rats (Figure 5a). In
contrast, in CCl4-treated rats, type IV collagen was
located along the fibrotic bands (Figures 5b through 5e).
Discussion
To the best of our knowledge, this study is the first to
present the development of an assay specific for a frag-
ment generated by the degradation of type IV collagen
by MMPs. This fragment may be a useful marker for
degradation of the basement membrane in tissue.
Type IV collagen is the most abundant structural
basement membrane component of tissue, with an
increase of 14-fold during fibrogenesis in the liver,
which is the highest relative increase among collagens
[18]. Several assays already exist for measuring total
type IV collagen in different pathologies by using poly-
clonal or monoclonal antibodies. Type IV collagen has
been studied in hepatitis C and nonalcoholic fatty liver
disease, and adequate diagnostic performance for
Figure 1 Standard curves. ELISA run showing typical standard curves and native reactivity against (A) Human serum, plasma, and (B) Rodents:
rat serum and plasma and mouse serum. Native material was run undiluted and at 1:2, 1:4 and 1:8 dilutions as indicated by dashed lines. The
signal is the optical density at 450 nm, subtracting the background at 650 nm, as a function of peptide concentration.
Figure 2 Assay characterization. Characterization of the
1438’GTPSVDHGFL’1447 (CO4-MMP) assay with regard to reactivity
against intact type IV collagen (CO4 intact), type IV collagen cleaved
by pepsin (CO4/pepsin), type IV collagen cleaved by matrix
metalloproteinase 2 (CO4/MMP-2), type IV collagen cleaved by
MMP-9 (CO4/MMP-9), type IV collagen cleaved by MMP-9 and
pepsin, elongated peptide with extension of one amino acid at the
neoepitope site, type I collagen cleaved by MMP-9 (CO1/MMP-9)
and type VI collagen cleaved by MMP-9 (CO6/MMP-9).
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significant fibrosis has been reported, particularly in
hepatitis C [19,20].
In our study, protease cleavage was performed by
incubating type IV collagen with various MMPs and
control proteases, after which fragments were identified
by MS analysis. Type IV collagen degradation resulted
in many unique fragments, among which was the CO4-
MMP fragment (GTPSVDHGFL). We consequently
developed a novel, technically robust ELISA with mono-
clonal antibodies to measure CO4-MMP
(GTPSVDHGFL) in serum. The assay had acceptable
inter- and intraassay variation, dilution recovery, spiking
recovery and LDL.
CO4-MMP levels were assessed in two different ani-
mal models of liver fibrosis: CCl4 and BDL. In both
models, we found significantly increased CO4-MMP
levels in rats with fibrotic livers compared with controls.
In addition, CO4-MMP levels were significantly corre-
lated with collagen deposition in the CCl4 model of liver
fibrosis. The data are in alignment data reported in
other studies in these animal models, demonstrating
that the presence of neoepitopes is a good biochemical
marker of pathologies involving excessive ECM remo-
deling [21-27]. A difference in the levels of CO4-MMP
in the BDL and CCl4 control/sham groups was
observed, which we attribute to the differences in age,
sex and strain of rats used. The animals in the CCl4
study were three-month-old male Wistar rats, whereas
BDL animals were six-month-old female Sprague-Daw-
ley rats.
It is well appreciated that the BDL and the CCl4 mod-
els describe two different fibrotic processes, although
increased ECM remodeling and excessive collagen
deposition are key characteristics of both. CO4-MMP
levels were significantly related to liver fibrosis in rats
treated with CCl4 for 12 to 20 weeks. The marker also
correlated highly significantly to total collagen in the
livers of CCl4-treated rats, albeit not in the control rats,
strongly indicating the fibrosis-specific pathological rele-
vance of the neoepitope. In the BDL model of liver
fibrosis, serum CO4-MMP was elevated one week after
BDL surgery compared to baseline and sham levels. The
serum CO4-MMP levels remained significantly
increased in rats studied for up to four weeks. These
data are in agreement with data reported in previous
studies, highlighting that type IV collagen is generated
during liver fibrogenesis by the activated hepatic stellate
cells in the liver [28] and that MMP levels become ele-
vated and imbalanced during fibrosis [1,29]. These data
support the hypothesis that liver fibrosis results not
Table 1 Percentage dilution recovery for the CO4-MMP
assaya
CO4-MMP, ng/mL HS1 63.0 HS2 73.7 RS1 42.2 RS2 38.4
Undiluted 100% 100% 100% 100%
Dilution 1:2 92.4% 99.6% 116.1% 108.7%
Dilution 1:4 101.5% 90.4% 123.7% 120.3%
Dilution 1:8 95.8% 91.5% 120.7% 126.9%
Dilution 1:16 80.4% 81.9% 117.5% 122.2%
Mean 92.5% 90.9% 119.5% 119.5%
aCO4-MMP = 1438’GTPSVDHGFL’1447; HS(1 or 2) = human serum samples; RS
(1 or 2) = rat serum samples. The percentages represents difference from a
undiluted sample.
Table 2 Inter- and intraassay variation for the CO4-MMP assays using human serum quality control samplesa
CO4-MMP sample Amount, ng/mL Intraassay variability, % Interassay variability, %
HS1 28.64 5.2 16.3
HS2 35.24 6.7 13.5
HS3 39.29 5.9 11.1
HS4 42.54 4.6 9.6
HS5 47.12 4.7 15.0
HS6 51.94 2.9 12.6
HS7 51.77 2.9 14.1
HS8 48.93 5.1 11.2
Mean 4.8 12.1
aCO4-MMP = 1438’GTPSVDHGFL’1447; The variation was calculated as the mean variation of ten individual determinations for each sample.
Table 3 Analyte stability in three rat and three human
serum samples in ten freeze-thaw cyclesa
Analyte stability Percentage recovery compared to 1 × freeze-
thaw cycle
Freeze-thaw cycles Human CO4-MMP Rat CO4-MMP
2 × 109.9 81.6
3 × 75.4 88.9
4 × 95.6 101.8
5 × 113.1 85.3
6 × 92.2 71.1
7 × 122.6 92.1
8 × 131.0 83.6
9 × 104.3 91.0
10 × 90.9 96.6
aAll data shown are percentage recovery compared to day 0 or day 1 freeze-
thaw cycle.
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simply from an increase in collagen formation, but
rather from an increase in both collagen degradation
and formation, with formation outpacing degradation
and leading to a net increase.
The presently reported data clearly demonstrate that
the ELISA measured exclusively degraded type IV col-
lagen, by MMP-9 or pepsin alone or together, and not
fibrillar collagens types I, II and III. Future detailed
examination of the precise analyte we identified for our
CO4-MMP assay may shed more light on the processes
leading not only to tissue degradation but also to tissue
formation. The current assay provides additional infor-
mation compared to that of total collagen assessment,
as this assessment exclusively detects type IV collagen
degradation in the face of a pool of type IV collagen
fragments of both formation and degradation, which
may better be considered turnovers markers
This study carries some limitations. One major limita-
tion of this study is that it was carried out in homoge-
neous, inbred laboratory rats with synchronous
induction of liver disease, which bears little resemblance
to the highly complicated clinical presentation of liver
fibrosis. Further investigations in clinical settings are
needed to provide more information on the usefulness
of the CO4-MMP biomarker.
The recent cloning and characterization of genes for col-
lagen IV have provided information on the structure,
expression and function of basement membranes during
development and diseases states. The important role of
collagen type IV is illustrated by the clinical consequences
of collagen IV mutations leading to, for example, Alport
syndrome caused by mutations in the a3 chain, HANAC
syndrome (hereditary angiopathy with nephropathy,
aneurysm and cramps) caused by mutations in the a1
chain, defects in Bowman’s capsule consisting of hypertro-
phy of parietal epithelium caused by a1 mutations, ante-
rior segment dysgenesis caused by a1 mutations and
Axenfeld syndrome caused by a5 mutations [8,9].
Type IV collagen forms a complex with many interac-
tions, including intrachain covalent bonds, as well as
Table 4 Spiking recovery in human seruma
Peptide concentration, ng/mL Peptide serum + peptide concentration, ng/mL Peptide recovered, ng/mL Recovery, %
31.1 145.3 31.1 103.5
13.4 135.3 13.3 110.4
7.6 125.7 7.6 107.6
4.7 121.6 4.7 106.7
0 109.2 0 100
aPeptide sample = native type IV collagen cleaved by matrix metalloproteinase 9 and pepsin. Recovery percentages are peptide concentrations compared to
peptide measured in serum after subtracting the serum background.
Figure 3 CO4-MMP serum levels in bile duct-ligated rats. Serum 1438’GTPSVDHGFL’1447 (CO4-MMP) was assessed in bile duct-ligated and
sham-operated rats at baseline and at death at weeks 1, 2, 3 and 4. The data presented are means ± standard errors of the mean (SEM).
Asterisks indicate statistical significance as indicated by bars (**P < 0.05, ***P < 0.001, ns = nonsignificant difference).
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interactions with most other constituents of the base-
ment membrane [6]. Thus, measurement of type IV col-
lagen may be different compared to the assays
developed for measurement of degradation of the fibril-
lar collagens types I, II and III [21,30-33]. The present
data clearly demonstrate that the ELISA measured
exclusively degraded type IV collagen. Others have used
pepsin-solubilized type IV collagen to assess serum
levels [34], as the protein is caught in a complex. The
CO4-MMP fragment was identified by MS data analysis
Figure 4 CO4-MMP serum levels in carbon tetrachloride-treated rats. (A) Serum 1438’GTPSVDHGFL’1447 (CO4-MMP) was assessed in control
rats at death (controls) as well as in carbon tetrachloride (CCl4)-treated rats at death at weeks 8, 12, 16 and 20. The results shown are means ±
SEM. (B) Serum CO4-MMP in all controls pooled and CCl4 rats stratified into quartiles according to total collagen in the liver. (C) Correlations
between CO4-MMP and Sirius red in (C) CCl4 rats and (D) control rats. Asterisks indicate statistical significance as indicated by bars (**P < 0.05,
***P < 0.001, ns = nonsignificant difference).
Figure 5 Type IV collagen in the liver. Immunohistochemical analysis of type IV collagen. Photomicrographs show hepatic structure in rats 20
weeks after vehicle treatment (a), after 8 weeks of carbon tetrachloride (CCl4) treatment (b), after 12 weeks of CCl4 treatment (c), after 16 weeks
of CCl4 treatment and (d) and after 20 weeks of CCl4 treatment. Original magnification, ×40.
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as being generated by MMP-2 and MMP-9, but only the
MMP-9-generated fragment was detected by the CO4-
MMP assay. Type IV collagen may be cleaved without
release of fragments that are bound to a multivalent
complex. This explains why we observed a stronger
reaction when we cleaved first with MMP-9 and then
with pepsin. Further research is needed to understand
which enzymes and their sequential activities are
involved in the degradation process.
Conclusions
In summary, we have developed an assay using a specific
monoclonal antibody for the detection of CO4-MMP, a
basement membrane degradation marker. We have
demonstrated that this marker was elevated in two pre-
clinical models of liver fibrosis, the BDL and the CCl4
rat models, indicating that this neoepitope may have
potential use in assessing diseases with high turnover of
the ECM.
Abbreviations
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